Cervenka J, Tlucková I
Bull World Health Organ. 1966;35(4):603-7.
It is well known that BCG vaccination in the newborn is particularly difficult to carry out with satisfactory results. The allergic response is delayed and weak in comparison with that in older children, and attempts to compensate for this by using a more potent vaccine often result in a high incidence of regional lymphadenitis. The preliminary results of a blind comparative trial, in newborn children, of BCG vaccine from Czechoslovakia. Denmark and Sweden are reported. There was no case of lymphadenitis in any of the three vaccine groups. The allergic reactions induced by the Danish and Swedish vaccines were of equal strength, although the vaccination scars from the Swedish vaccine were slightly larger. The vaccine from Czechoslovakia produced strikingly weaker allergic reactions as well as definitely smaller scars than the other two vaccines.
众所周知，新生儿接种卡介苗特别难以取得令人满意的效果。与大龄儿童相比，其过敏反应出现延迟且较弱，而试图通过使用更强效的疫苗来弥补这一情况，往往会导致局部淋巴结炎的高发病率。本文报道了一项针对新生儿的卡介苗盲法对比试验的初步结果，该试验使用了来自捷克斯洛伐克、丹麦和瑞典的卡介苗。三个疫苗组均未出现淋巴结炎病例。丹麦和瑞典的疫苗引发的过敏反应强度相当，不过瑞典疫苗接种后的疤痕略大。与其他两种疫苗相比，捷克斯洛伐克的疫苗引发的过敏反应明显较弱，且疤痕也明显更小。
